RxDoctor Payments Data

Joseph Lane, MD

Orthopaedic Surgery · New York, NYNPI 1144245747

Payments from drug & device makers

$136,899in general payments, 2019–2025

Across 132 payments — averaging $1037.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Radius Health, Inc.$111K
  • Lenoss Medical Inc$14K
  • Amgen$4K
  • UCB SA$4K
  • Novartis$2K
  • Stryker$827
  • plus $609 from 6 others
$2,741in research payments, 2019–2025

Across 6 payments — averaging $456.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$3K

What the payments were for

  • Consulting fees$20,75083%
  • Food & beverage$3,92316%
  • Education$1871%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Radius Health, Inc.39$111,047
Lenoss Medical Inc3$14,250
Amgen41$3,949
UCB SA1$3,880
Novartis1$2,338
Stryker41$827
Arteriocyte Medical Systems, Inc.1$144
AstraZeneca1$134
Terumo BCT, Inc.1$128
Kuros Biosciences USA, Inc1$101
Cerapedics Inc.1$99
Si-bone, Inc.1$2

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$136,899 in reported general payments places this provider in the 90th percentile of 1,079 orthopaedic surgery providers in New York.

See all orthopaedic surgery providers in New York

Medicare billing

Part B allowed, 2024
$256,998
Medicare patients
1,252
Services billed
2,173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TymlosAbaloparatide513$1,398,624
Teriparatide141$380,723
ForteoTeriparatide79$334,225
Evenity (2 Syringes)Romosozumab-Aqqg22$57,175
ProliaDenosumab18$29,482
Calcitriol94$2,516
Calcitonin-SalmonCalcitonin,salmon,synthetic27$1,429
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic27$1,336
Ultra-Fine Short Pen NeedlePen Needle, Diabetic14$790
Alendronate Sodium111$777
Diclofenac Sodium23$704
Meloxicam33$199
Hydrochlorothiazide13$181
Unifine PentipsPen Needle, Diabetic11$0

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Radius Health, Inc.Tymlos$111,047$1,398,624513 claims
AmgenEvenity (2 Syringes), Prolia$3,949$86,65640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,079 orthopaedic surgery providers in New York.

Other orthopaedic surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →